Niraparib

Key facts

Drug.legal_AU

S4

Drug.image

Niraparib.svg

Drug.image_class

skin-invert-image

Drug.caption

Above: molecular structure of niraparib Below: 3D representation of a niraparib molecule

Drug.image2

Niraparib 3D.png

Drug.image_class2

bg-transparent

Drug.tradename

Zejula

Drug.MedlinePlus

a617007

Drug.DailyMedID

Niraparib

Drug.pregnancy_AU

D

Drug.routes_of_administration

By mouth

Drug.ATC_prefix

L01

Drug.ATC_suffix

XK02

Drug.legal_CA

Rx-only

Drug.legal_CA_comment

/ Schedule D

Drug.legal_UK

POM

Drug.legal_US

Rx-only

Drug.legal_EU

Rx-only

via Wikipedia infobox

Chemical data

Formula

C19H20N4O

Molecular weight

320.4 g/mol

IUPAC name

2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide

SMILES

C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N

InChIKey

PCHKPVIQAHNQLW-CQSZACIVSA-N

XLogP

2.2

Polar surface area

72.9 Ų

H-bond donors

2

H-bond acceptors

3

Formal charge

0

via PubChem

Drug data · ChEMBL

Max clinical phase

Approved

Molecule type

Small molecule

First approval

2017

Admin. routes

oral

Indications

ovarian carcinoma, neoplasm, prostate adenocarcinoma, Hereditary breast and ovarian cancer syndrome

via ChEMBL · EBI

• Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2024
• Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
• Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.The New England journal of medicine · 2019
• Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.The New England journal of medicine · 2016
• Niraparib.2012

via PubMed

Wikidata facts

Subclass of

chemical compound

Mass

320.164

via Wikidata · CC0